Healthcare / BiotechnologyNasdaqCM
$0.27
+0.00 (+1.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-3.9M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$12M
P/E
N/A
•EV/EBITDA
N/A
•ROE
471.9%
↑Gross Margin
80.6%
↑Debt/Equity
-2.90
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-54.6%
FCF CAGR
—
FCF margin
-24838.2%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21796.0 · net income $-8.6M · FCF $-5.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21796.00 | $21796.00 | — | — | $233281.00 |
| Net Income | $-8.6M | $-8.6M | $-2.4M | $-4.8M | $-5.0M |
| EBITDA | $-8.6M | $-8.6M | $-2.2M | $-4.6M | $-4.2M |
| EPS | — | — | -0.08 | -0.18 | -0.15 |
| Gross Margin | 80.6% | 80.6% | — | — | — |
| Operating Margin | -40873.2% | -40873.2% | — | — | -1471.4% |
| Net Margin | -39662.8% | -39662.8% | — | — | -2125.2% |
| Balance Sheet | |||||
| Debt/Equity | -2.90 | -2.90 | 0.05 | -0.39 | -0.27 |
| Current Ratio | 0.65 | 0.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.4M | $-5.4M | $-3.9M | $-480953.00 | $-1.2M |
| Returns | |||||
| ROE | 471.9% | 471.9% | -58.5% | 82.5% | 69.4% |
| Valuation | |||||
| P/B | — | — | 58.64 | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 55.6% | -19.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-67.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → n/d
Residual
-67.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.